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Abstract
AIM: To evaluate the potential of thioredoxin (TXN) 
and thioredoxin-interacting protein (TXNIP) expression 
as biomarkers for predicting gastric cancer recurrence.
METHODS: TXN and TXNIP expression levels were 
acquired from gene expression microarray data for 65 
human gastric cancer tissues. We determined whether 
each gene expression level was associated with cancer 
recurrence and investigated the relationship between 
the two genes. For validation, the expression levels of 
TXN and TXNIP were measured by quantitative real-
time reverse transcription polymerase chain reaction in 
68 independent stage Ⅲ gastric cancer patients. The 
correlation between gene expression and cancer prog-
nosis was evaluated. Immunohistochemical staining 
was performed to investigate the protein expression 
levels of TXN and TXNIP and to characterize the ex-
pression patterns of each protein.
RESULTS: TXN was a prognosis-related gene (P  = 
0.009), whereas TXNIP, a TXN inhibitor, demonstrated 
a negative correlation with TXN in the gene expres-
sion microarray data. In the 68 stage Ⅲ patients, the 
expression levels of both TXN and TXNIP had a sta-
tistically significant effect on recurrence-free survival 
(RFS, P  = 0.008 and P  = 0.036, respectively). The low 
TXN and high TXNIP expression group exhibited a bet-
ter prognosis than the other groups, and the high TXN 
and low TXNIP expression group exhibited a poorer 
prognosis (P  < 0.001 for RFS and P  = 0.001 for overall 
survival). More than half of the patients in the simulta-
neously high TXN and low TXNIP expression group ex-
perienced a recurrence within 1 year after curative sur-
gery, and the 5-year survival rate of the patients in this 
group was 29%, compared with 89% in the low TXN 
and high TXNIP expression group. The TXN protein 
was overexpressed in 65% of the gastric cancer tis-
sues, whereas the TXNIP protein was underexpressed 
in 85% of the cancer cells. In a correlation analysis, 
TXN and TXNIP were highly correlated with many on-
cogenes and tumor suppressors as well as with genes 
related to energy, protein synthesis and autophagy.
CONCLUSION: TXN and TXNIP are promising prog-
nostic markers for gastric cancer, and performing per-
sonalized adjuvant treatment based on TXN and TXNIP 
expression levels would be an effective practice in the 
treatment of gastric cancer.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Gastric cancer is the second leading cause of  global 
cancer mortality, and it has the highest mortality rates 
in East Asia, including South Korea, Japan and China[1]. 
The standard treatment for gastric cancer is surgery. 
However, relapses occur in many patients who undergo 
curative resection, even after adjuvant therapy[2,3]. Even 
among individuals with the same stage of  cancer, gastric 
cancer patients present with diverse clinical manifesta-
tions and prognoses. The clinical diversity of  gastric 
cancer arises from its molecular biological diversity, 
which is caused by changes in different genes. Molecular 
markers are important in predicting patient outcome and 
in personalizing treatments according to the individual 
biology of  the patient. Importantly, in the adjuvant treat-
ment setting, uniform adjuvant treatment after curative 
resection of  gastric cancer has been performed regard-
less of  the individual molecular prognostic markers of  
the cancer. However, cancer researchers have identified 
biomarkers that can predict recurrence and survival[4-8], 
and doctors should consider using biomarker-driven per-
sonalized adjuvant treatment.
Thioredoxin (TXN) is a low-molecular-weight redox 
protein and a putative oncoprotein that provides growth 
and survival advantages to tumor cells through the acti-
vation of  redox-sensitive transcription factors, such as 
nuclear factor kappa B (NF-κB), p53, and activator pro-
tein-1 (AP-1)[9,10]. TXN inhibits apoptosis via apoptosis 
signaling kinase-1 (ASK-1) and phosphatase and tensin 
homolog (PTEN)[11]. TXN also induces hypoxia-inducible 
factor-1α (HIF-1α), which increases the production of  
vascular endothelial growth factor and leads to tumor an-
giogenesis and drug resistance[12]. The overexpression of  
TXN has been found in several cancers, including lung[13], 
pancreatic[14], cervical[15], and colorectal cancers[16] as well 
as hepatomas[17]. The increased expression of  TXN in 
tumors has been associated with decreased patient sur-
vival in several cancers and with resistance to anticancer 
drugs[18,19]. The TXN-interacting protein (TXNIP), also 
known as vitamin D3 up-regulated protein-1 (VDUP1) 
and TXN-binding protein-2 (TBP-2), inhibits the interac-
tion between TXN and other factors. TXNIP overexpres-
sion inhibits TXN activity, which in turn inhibits tumor 
cell proliferation and cell cycle progression[20,21]. Recently, 
it was reported that knockout of  the TXNIP gene in a 
mouse model induced Helicobacter pylori (H. pylori)-related 
gastric cancer[22]. However, there is little information re-
garding the prognostic value of  the expression level of  
TXN and TXNIP in gastric cancer.
In this study, we evaluated the use of  TXN expres-
sion combined with TXNIP expression as prognostic 
markers to individualize the postoperative treatment 
strategy following gastric cancer removal.
MATERIALS AND METHODS
Gene expression microarray data analysis
The previously generated gene expression data from 
gastric cancer patients are available in the NCBI’s GEO 
public database (microarray data accession number, 
GSE13861)[23]. Sixty-five gastric cancer patients under-
went curative surgery as a primary treatment, with clini-
cal data obtained from the Yonsei University Severance 
Hospital (Table 1). Sixty-five surgically removed frozen 
gastric adenocarcinoma tissues and 19 normal surround-
ing tissue samples were used for the microarray experi-
ments. The total RNA was extracted from the fresh-
frozen tissues using a mirVana RNA Isolation Labeling 
Kit (Ambion, Austin, TX, United States). For the labeling 
and hybridization, 500 ng of  total RNA was used, ac-
cording to the manufacturer’s protocols (Human-HT12 v.3 
Expression BeadChip, Illumina, San Diego, CA, United 
States). The microarray data were normalized using the 
quantile normalization method in the Linear Models for 
Microarray Data package in the R language environment. 
The expression level of  each gene was transformed into 
a log2 base prior to further analysis. The random variance 
t test was applied to identify the differentially expressed 
genes between the two tissue types. The gene expression 
differences were considered significant if  the P value 
was less than 0.001. Cluster analysis was performed with 
Cluster 3.0 and TreeView[24]. Univariate analysis was per-
formed by dividing the patients into two groups based on 
the median value of  each gene expression level to search 
for prognostic genes. 
Quantitative reverse transcription-polymerase chain reaction 
and analysis
Paraffin-embedded cancer tissues were collected from 
gastric adenocarcinoma patients who underwent curative 
surgery between 1999 and 2007 as a primary treatment 
at Gangnam Severance Hospital. The clinical data of  the 
patients were reviewed to obtain age, sex, tumor location, 
tumor differentiation, and stage based upon the American 
Joint Committee on Cancer 2002 criteria. The patients 
were followed up for more than 36 mo after surgery or 
until recurrence or death within 36 mo after surgery.
Sixty-eight stage Ⅲ gastric cancer tissues were cho-
sen to validate the microarray data (Table 1). The total 
RNA was extracted according to the manufacturer’s 
instructions (RecoverAll™ Total Nucleic Acid Isolation; 
Applied Biosystems, Foster City, CA, United States). The 
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TXN and TXNIP genes were assayed using quantitative 
reverse transcription-polymerase chain reaction (qRT-
PCR) with TaqMan gene-specific primers (Applied Bio-
systems, Foster City, CA, United States). Real-time RT-
PCR amplification was performed using the 7900HT Fast 
Real-Time PCR System with a 384-well block module 
(Applied Biosystems, Foster City, CA, United States). The 
cycling conditions were as follows: 48 ℃ for 30 min and 
95 ℃ for 10 min, followed by 40 cycles at 95 ℃ for 15 s 
and at 60 ℃ for 60 s. The relative amounts of  mRNA 
were calculated from the threshold cycle (CT) number 
using the expression of  b-2 microglobulin as an endog-
enous control. All of  the experiments were performed 
in triplicate, and the values were averaged. 
Tissue microarray construction and immunohistochemical 
staining
Paraffin-embedded tissue microarray blocks of  gastric 
cancer tissue specimens were created from tissues from 
328 patients. Each block had 3-mm cores of  gastric can-
cer tissue. The 4-μm thick sections were deparaffinized 
and processed to block endogenous peroxidase activity. 
Next, an antigen retrieval step was performed. Subse-
quently, primary anti-TXN (Polyclonal, 1:500, Abcam, 
Cambridge, MA, United States) and anti-TXNIP anti-
bodies (Polyclonal, 1:100 Sigma, St. Louis, MO, United 
States) were applied to the sections. The sections were 
then incubated with a secondary antibody (HRP-rabbit/
mouse), and the stains were developed using a Nova-
RED substrate kit (VECTOR Laboratory, Burlingame, 
CA, United States). The samples were then counter-
stained with Harris hematoxylin.
The TXN and TXNIP protein expression levels 
were evaluated by two pathologists. Over-expression was 
defined as staining higher in more than 50% of  cancer 
cells compared to the matching normal cells, regardless 
of  cytoplasmic or nuclear location. Underexpression was 
defined as no staining or staining positivity lower than 
that of  the matching normal tissue, and normal expres-
sion was defined as a level of  staining positivity similar 
to that of  the matching normal tissue. For slides that 
were heterogeneously stained within a tumor, we graded 
the highest intensity within the tumor.
Statistical analysis 
The BRB-Array Tools system was used for the analysis 
of  the microarray data. Statistical analysis were primarily 
performed with PASW Statistics 17.0 (SPSS Inc., Chica-
go, IL, United States). A χ 2 test was used to compare the 
difference between the groups. Kaplan-Meier plots and 
a log-rank test were used to estimate patient survival. 
Associations between the expression levels of  the two 
targets and in-trans correlation were analyzed using the 
Pearson correlation coefficient. A P value of  less than 
0.05 was considered statistically significant, and all tests 
were two tailed.
RESULTS
Expression of TXN mRNA in microarray data for gastric 
cancer
First, a hierarchical clustering analysis was applied to the 
gene expression data from the 65 human primary tumor 
tissue samples. Unsupervised clustering revealed 2 dis-
tinctive subtypes with clear differences in overall gene 
expression patterns[23]. Recurrence-free survival (RFS) 
was found to differ significantly between the 2 clusters 
(P = 0.001 by the log rank test), indicating that the mo-
lecular features of  these tumors reflected in gene expres-
sion patterns might be strong independent predictors of  
clinical outcomes. 
We next sought to identify genes whose expression 
was unique to the poor prognostic subgroup by cross-
comparing gene lists. Between the two groups, 1258 
genes were differentially expressed (P < 0.001) and pre-
sented more than a 1.5-fold difference between the two 
groups. Next, a univariate analysis identified 84 prognos-
tic genes (P < 0.01). Of  the 84 genes, TXN was a prog-
nosis-related gene (P = 0.009 by univariate analysis) and 
was up-regulated in the poor prognostic group. From 
the correlation analysis between the expression levels of  
TXN and associated genes, we determined the relative 
correlations. TXNIP, a TXN inhibitor, demonstrated a 
negative correlation with TXN (r = -0.295, P = 0.024). 
The survival analysis based on the hierarchical clustering 
of  TXN- or TXNIP-related genes demonstrated that 
each cluster influenced patient survival (P = 0.025 and P 
= 0.036, respectively) (Figure 1). 
 
qRT-PCR validation of TXN and TXNIP expression
To determine if  TXN and TXNIP gene expression was 
associated with prognosis among patients with the same 
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Table 1  Clinicopathological factors of the gastric cancer patients
Characteristics    Microarray 
    (n  = 65)
   qRT-PCR 
   (n  = 68)
  TMA 
   (n  = 328)
Age 
   mean (range), yr 63 (32-83) 56 (26-82)   57 (25-82)
Sex, n (%)
   Male/female 46 (71)/19 (29) 36 (53)/32 (47) 204 (62)/124 (38)
Follow up duration
   Mean (95% CI), mo 41.7 (41-42) 89.5 (79-100)   99.8 (97.5-102)
Histological type, n (%)
   Intestinal 23 (35) 14 (21) 100 (30)
   Diffuse 42 (65) 54 (79) 228 (70)
TNM stage, n (%)
   Ⅰ 12 (18)   0 101 (31)
   Ⅱ 11 (17)   0   79 (24)
   Ⅲ 26 (40) 68 (100) 110 (33)
   Ⅳ 16 (25)   0   38 (12)
Location, n (%)
   Cardia 5 (8)   8 (12)   25 (8)
   Non cardia 60 (92) 60 (88) 303 (92)
Adjuvant chemotherapy, n (%)
   Yes 49 (75) 59 (87) 230 (70)
   No 16 (25)   9 (13)   98 (30)
qRT-PCR: Quantitative reverse transcription-polymerase chain reaction; 
TMA: Tissue microarray; TNM: Tumor node metastasis.
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stage of  cancer, 68 stage Ⅲ patients were randomly se-
lected for qRT-PCR analysis (Table 1). The median fol-
low-up duration after curative resection was 89.5 mo. By 
the last follow-up visit, 44 patients had experienced a re-
currence, and 16 patients had died of  gastric cancer. The 
patients were divided into high or low expression groups 
according to the TXN and TXNIP expression levels. RFS 
and overall survival (OS) were analyzed between the two 
groups (Figure 2A-D). Both TXN and TXNIP expression 
influenced RFS, and these associations were significant (P 
= 0.008 and P = 0.036, respectively). The patients in the 
high TXN expression or low TXNIP expression groups 
presented a poor prognosis. TXN expression also influ-
enced OS (P = 0.015), but TXNIP expression did not 
have a significant relationship with OS (P = 0.053). 
Stage Ⅲ patients were classified into the following 
three combination groups based on the TXN and TXNIP 
expression levels: Group 1, simultaneously low TXN and 
high TXNIP levels (n = 20); Group 2, neither Group 1 
nor Group 3 (n = 35); and Group 3, simultaneously high 
TXN and low TXNIP levels (n = 13). As expected, Group 
1 exhibited a better prognosis than the other groups, and 
Group 3 presented with a poor prognosis (Figure 2E and F; 
P < 0.001 for RFS and P = 0.001 for OS). More than half  
of  the Group 3 patients experienced a recurrence within 1 
year after curative surgery, and their 5-year survival rate was 
one-third (29%) that of  Group 1 (89%) (Table 2). There 
was no relationship between the TXN/TXNIP expression 
levels and either tumor stage or histological cell type. 
Immunohistochemical assay of TXN and TXNIP expression
The gastric glands were relatively well stained with the 
anti-TXN antibody regardless of  the presence of  cancer-
ous and non-cancerous lesions based on the immunohis-
tochemical assay results. Thioredoxin was overexpressed 
in approximately 65% of  cancer tissues regardless of  the 
histological type and TNM stage (Table 3). Thioredoxin 
staining was observed in the cytoplasm or nucleus or in 
both areas of  the cancer cells. The histological location of  
thioredoxin in the cytoplasm or the nucleus in cancer tis-
sues varied among patients, and there was heterogeneity in 
the staining intensity within the individual samples. In con-
trast to the staining with the anti-thioredoxin antibody, the 
staining of  the gastric cancer tissue with the anti-TXNIP 
antibody was weak. TXNIP was underexpressed in almost 
85% of  the cancer cells and was found in the cytoplasm 
or nucleus of  the cancer cells. There was a tendency for 
TXNIP to be underexpressed in two poor prognosis 
groups: diffuse histology type (P = 0.009) and high-stage 
gastric cancer (P = 0.011) (Table 3). Representative immu-
nohistochemical staining results are shown in Figure 3.
Bioinformatic in-trans correlation analysis of TXN and 
TXNIP expression 
Approximately 7000 genes were significantly correlated 
with TXN according to the bioinformatic in-trans cor-
relation analysis of  TXN expression with whole mRNA-
expressing genes (P < 0.001). These findings suggest 
that TXN plays an important role in gastric cancer. Glu-
taredoxin 2 (GLRX2) and peroxiredoxin 4 (PRDX4) 
were highly correlated with TXN (r = 0.76, P < 0.001 
and r = 0.72, P < 0.001, respectively; Table 4), and this 
correlation explains the function of  TXN as a reactive 
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Figure 1  Survival analysis based on hierarchical clustering of thioredoxin 
or thioredoxin-interacting protein correlated genes.
Table 3  Protein expression of thioredoxin and thioredoxin-
interacting protein in gastric cancers
Characteristic (n ) TXN overexpression
          n  (%)
TXNIP underexpression 
            n  (%)
Total (328)            213 (65)            278 (85)
Histologic type
   Diffuse type (228)            149 (65)            201 (88)
   Intestinal type (100)              64 (64)              77 (77)
            P = 0.9            P = 0.012
Stage
   Stage Ⅰ/Ⅱ (180)            116 (64)            142 (79)
   Stage Ⅲ/Ⅳ (148)              97 (66)            136 (92)
           P = 0.767            P = 0.009
TXN: Thioredoxin; TXNIP: Thioredoxin-interacting protein.
Table 2  Prognoses of stage Ⅲ gastric cancer patients accord-
ing to the thioredoxin and thioredoxin-interacting protein 
gene expression levels
Group Mean RFS, 
(95% CI), mo
3-yr recurrenc-
e-free rate (%)
5-yr surviv-
al rate (%)
1: Low TXN and high TXNIP Non applicable           70         89
2: Neither group 1 nor group 3 36.7 (15.5-57.9)           51         73
3: High TXN and low TXNIP 11.9 (9.5-14.2)             7         29
P value by log rank test      P < 0.001   P = 0.001
RFS: Recurrence-free survival; TXN: Thioredoxin; TXNIP: Thioredoxin-
interacting protein.
Lim JY et al . Thioredoxin and thioredoxin-interacting protein in gastric cancer
5585 October 21, 2012|Volume 18|Issue 39|WJG|www.wjgnet.com
100
  80
  60
  40
  20
    0
O
S 
(%
)
P  = 0.015
TXN high expression
TXN low expression
0      20    40     60    80    100   120  140
t /mo
100
  80
  60
  40
  20
    0
R
FS
 (
%
)
P  = 0.008
TXN high expression
TXN low expression
0       20     40      60      80     100    120
t /mo
100
  80
  60
  40
  20
    0
R
FS
 (
%
)
P  = 0.036
TXNIP high expression
TXNIP low expression
0       20     40      60      80     100    120
t /mo
100
  80
  60
  40
  20
    0
O
S 
(%
)
P  = 0.053
TXNIP high expression
TXNIP low expression
0      20    40     60    80    100   120  140
t /mo
100
  80
  60
  40
  20
    0
R
FS
 (
%
)
P  < 0.001
Group 3
0       20     40      60      80     100    120
t /mo
Group 2
Group 1
100
  80
  60
  40
  20
    0
O
S 
(%
)
P  = 0.001
0      20    40     60    80    100   120  140
t /mo
Group 3
Group 2
Group 1
A B C
FED
Figure 2  Kaplan-Meier plot of recurrence-free survival and overall survival according to gene expression. Gene expression was measured using quantitative 
reverse transcription-polymerase chain reaction. Stage III gastric cancer patients were divided into two or three groups according to their gene expression levels. A, 
B: Survival curves according to thioredoxin (TXN) expression level; C, D: Survival curves according to thioredoxin-interacting protein (TXNIP) expression levels; E, F: 
Survival curves according to the combination of the TXN and TXNIP expression levels (Group 1: Simultaneous low TXN and high TXNIP expression; Group 2: Neither 
group 1 nor group 3; Group 3: Simultaneous high TXN and low TXNIP expression). The prognosis was compared across the groups using the log-rank test.
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Figure 3  Representative images of immunohistochemical assay (×400). A: The cytoplasm of gastric cancer cells was strongly stained with the anti-thioredoxin 
(TXN) Ab; B: The cytoplasm of gastric cancer cells was not stained with the anti-TXN Ab; C: The nuclei of gastric cancer cells were strongly stained with the anti-TXN 
Ab; D; The nuclei of gastric cancer cells were not stained with the anti-TXN Ab; E: The cytoplasm of gastric cancer cells was strongly stained with the anti-thioredoxin-
interacting protein (TXNIP) Ab, but the nuclei were not stained; F: The nuclei of gastric cancer cells were strongly stained with the anti-TXNIP Ab, but the cytoplasm 
was not stained.
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oxygen species (ROS) scavenger with these known redox 
molecules. Ribosomal proteins and mitochondrial ribo-
somal proteins (i.e., RPL6, RPL29, MRPL22, MRPL42, 
MRPS17 and ATP5S) were highly correlated with TXN 
(P < 0.001; Table 4), which suggests the active involve-
ment of  TXN in protein synthesis and mitochondrial 
ATP synthesis for energy production. TXNIP was nega-
tively correlated with TXN and known poor prognostic 
markers, such as AURKA, ERBB3, CCNB1, and many 
genes that are significantly correlated with TXN (Table 4). 
These results indirectly support the functional role of  
the TXNIP in the inhibition of  TXN. 
DISCUSSION
We demonstrated that TXN and TXNIP are poor and 
good prognostic gastric cancer markers, respectively. In 
stage Ⅲ patients who underwent curative gastrectomy, 
the 3-year recurrence-free rate (P < 0.001) and the 5-year 
survival rate (P = 0.001) were significantly different be-
tween patients with different TXN and TXNIP expres-
sion levels (Table 2). High TXN and low TXNIP patients 
had a definitively poor prognosis. Most of  these patients 
experienced a recurrence within 2 years and died within 4 
years. Thus, it is necessary to perform intensive treatment 
and plan post-adjuvant treatment for these patients.
The gene expression microarray data imply that TXN 
plays an important role in gastric cancer. TXN functions 
as a ROS scavenger with known redox molecules, such 
as GLRX2 and PRDX4, and TXN is actively involved in 
protein synthesis and mitochondrial ATP synthesis for 
energy production. Hypoxia-induced genes [i.e., ERO1L 
and hypoxia inducible gene 2 (HIG2)] were significantly 
correlated with TXN. Tumors with high TXN expression 
also exhibited elevated ERO1L and HIG2 levels; there-
fore, these tumors are in a relatively high hypoxic state 
compared with tumors with low TXN expression. Addi-
tionally, autophagy-related genes (i.e., ATG10, ATG16L2, 
and ATG12) were negatively correlated with TXN expres-
sion, which indirectly suggests that TXN is involved in 
autophagic inhibition in a hypoxic cancer state. Autophagy 
is associated with cancer pathogenesis and chemotherapy 
resistance; therefore, the function of  TXN in autophagy 
should be elucidated through additional studies.
Grogan et al[25] demonstrated that TXN was localized 
to tumor cells and was overexpressed in gastric cancer tis-
sues compared with the levels in normal gastric mucosa. 
TXN overexpression was typically found in both the nu-
cleus and the cytoplasm of  neoplastic cells. These findings 
are consistent with our immunohistochemical staining 
results. Furthermore, high TXN expression was observed 
regardless of  the gastric cancer stage or cell type. 
Our study confirmed that TXNIP was significantly 
underexpressed in gastric cancer tissues compared with 
normal tissues; furthermore, it was expressed at the low-
est levels in cancer patients with poor prognoses. TXNIP 
is a known potent tumor suppressor whose expression is 
markedly decreased in various human cancers, including 
gastric cancer. Knockout of  the TXNIP gene in a mouse 
model was associated with H. pylori-related gastric can-
cer[22]. In an in vitro experiment, TXNIP overexpression in 
pancreatic cells resulted in a higher basal level of  apopto-
sis and an increased sensitivity to cisplatin and oxalipla-
tin[26]. In microarray data analysis, TXNIP expression was 
negatively correlated with the expression of  TXN expres-
sion, known as poor prognostic cancer biomarkers[27-29], 
and many genes that are significantly correlated with 
TXN. These results indirectly confirm the functional role 
of  the TXNIP in TXN inhibition. Additionally, autopha-
gy-related genes were correlated with TXNIP, and these 
data support that TXNIP induces cancer cell autophagy.
In this study, we analyzed the gene expression profile 
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Table 4  In-trans correlation analysis of thioredoxin and thioredoxin-interacting protein with whole mRNA expressing genes
Symbol Gene name      Correlation with TXN    Correlation with TXNIP
   r P  value     r  P  value
TXN Thioredoxin  1.000    0.000 -0.295    0.022
RPL6 Ribosomal protein L6  0.779 < 0.001 -0.335    0.009
GLRX2 Glutaredoxin 2  0.764 < 0.001 -0.314    0.015
RPL29 Ribosomal protein L29  0.757 < 0.001 -0.360    0.005
MRPL22 Mitochondrial ribosomal protein L22  0.751 < 0.001 -0.225    0.085
MRPL42 Mitochondrial ribosomal protein L42  0.734 < 0.001 -0.181    0.166 
MRPS17 Mitochondrial ribosomal protein S17  0.732 < 0.001 -0.387    0.002
ATP5S ATP synthase-coupling factor B   0.728 < 0.001 -0.182    0.165
PRDX4 Peroxiredoxin 4  0.722 < 0.001 -0.321    0.012
AURKA Aurora kinase A  0.611 < 0.001 -0.486 < 0.001
ERO1L ERO1-like  0.586 < 0.001 -0.200    0.125
HIG2 Chromosome 7 open reading frame 68  0.574 < 0.001 -0.089    0.498
CCNB1 Cyclin B1  0.563 < 0.001 -0.503 < 0.001
ERBB3 HER3  0.004    0.975 -0.536 < 0.001
TXNIP Thioredoxin interacting protein -0.295    0.022  1.000    0.000
ATG12 ATG12 autophagy related 12 homolog -0.482 < 0.001  0.072    0.582
ATG16L2 ATG16 autophagy related 16-like 2 -0.722 < 0.001  0.216    0.098
ATG10 Autophagy related 10 homolog -0.756 < 0.001  0.266    0.040
TXN: Thioredoxin; TXNIP: Thioredoxin-interacting protein.
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of  human gastric cancer to identify potential biomark-
ers that could be used to classify patients according to 
prognosis after curative resection. We found that TXN 
and TXNIP were significantly associated with prognosis. 
TXN up-regulation and the simultaneous down-regula-
tion of  TXNIP were associated with a poor prognosis 
in gastric cancer patients. Bioinformatic analysis revealed 
that TXN and TXNIP were highly correlated with many 
oncogenes and tumor suppressor genes and demonstrat-
ed that TXN and TXNIP were associated with genes re-
lated to energy, protein synthesis and the modulation of  
autophagy under hypoxic or other stressful conditions. 
One of  the limitations of  this study is that we did not 
elucidate how TXN and TXNIP affect the recurrence of  
gastric cancer after curative resection. Further investiga-
tion of  TXN and TXNIP in gastric cancer would likely 
identify unknown pathogenic mechanisms. In addition, 
because our results were derived from retrospective as-
sessment, it is necessary to utilize TXN and TXNIP gene 
expression-based prediction in a prospective randomized 
trial(s) to validate the true clinical relevance of  TXN and 
TXNIP. It will be beneficial to identify effective anti-tu-
mor treatments other than the current standard adjuvant 
chemotherapy for gastric cancer patients with potent re-
currence factor, high TXN and low TXNIP expression. 
Furthermore, TXN-targeted agents or those that up-
modulate TXNIP could be used in targeted therapy in 
the treatment of  gastric cancer patients who are selected 
based on biomarker gene signatures.
In conclusion, TXN and TXNIP are promising prog-
nostic markers for gastric cancer, and performing per-
sonalized adjuvant treatment based on TXN and TXNIP 
expression levels would be an effective practice in the 
treatment of  gastric cancer.
COMMENTS
Background
The standard of treatment for gastric cancer is surgery. After curative resection, 
even among individuals with the same stage of cancer, diverse recurrence pat-
terns are present. However, uniform adjuvant treatment after curative resection 
has been performed. Authors evaluated the use of thioredoxin (TXN) expres-
sion combined with thioredoxin-interacting protein (TXNIP) expression as prog-
nostic markers to individualize the postoperative treatment strategy following 
gastric cancer removal. 
Research frontiers
TXN is putative oncoprotein that provides growth and survival advantages to tumor 
cells through the activation of redox-sensitive transcription factors. TXNIP is a potent 
tumor suppressor and inhibits the interaction between TXN and other factors. They 
have been recognized as cancer-related markers in diverse malignancies. 
Innovations and breakthroughs
High TXN and low TXNIP expression in human gastric cancer tissue definitively 
related with poor prognosis of gastric cancer patients who had undergone cura-
tive resection. 
Applications 
The establishment of adjuvant treatment strategy based on our discovery would 
be useful to accomplish better outcomes after surgical treatment. The patients 
with high TXN and low TXNIP expressions in cancer tissue require novel treat-
ment and should be more carefully monitored after surgery. 
Terminology
Redox (reduction-oxidation) reactions: Many important biological processes in-
volve redox reactions. Free radicals are a part of redox molecules and can be-
come harmful to the human body if they do not reattach to the redox molecule 
or an antioxidant. Unsatisfied free radicals can trigger the mutation of cells they 
encounter and are thus cancer causing. 
Peer review
This study investigated the potential of TXN and TXNIP genes as a prognostic 
marker after curative resection of gastric cancer. Patients with high TXN and 
low TXNIP expression in cancer tissue manifested significantly more recurrence 
and shorter survival. However, it is necessary to validate through the prospec-
tive trial and to elucidate the functional mechanism of TXN and TXNIP.
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